Praxis Precision to present preclinical, clinical data from epilepsy programs

Praxis Precision (PRAX) Medicines announced that that it will present preclinical and clinical data from three of its epilepsy programs at the American Epilepsy Society, AES, Annual Meeting, being held from December 6 to 10, 2024 in Los Angeles, California. “At Praxis, we are on the brink of transformative change with a leading pipeline that includes relutrigine and vormatrigine, the most potent and most functionally selective anti-seizure medications developed to date,” said Steven Petrou, chief scientific officer and co-founder of Praxis. “Following promising results with the relutrigine EMBOLD study in particularly challenging childhood epilepsies, we are confident that these future therapies will redefine treatment for DEEs as well as focal and generalized epilepsy. This year at AES we will be sharing the latest advances across our epilepsy portfolio through an exciting lineup of activities.”